Aarti Drugs’ recent expansion goes beyond just increasing manufacturing capacity. The company has invested approximately ₹600 crore in various projects aimed at enhancing capacity, backward integration, and asset utilization. The key question is how much of the benefit will show up as higher reported revenue versus lower input costs and improved margins from captive consumption.
Aarti Drugs was trading around ₹415 per share, with a market capitalization of roughly ₹3,788 crore and a P/E of around 20x. The stock’s 52-week range was approximately ₹319–₹534.
Sayakha Creates A Different Payoff
The Sayakha facility is particularly important because it produces di-, mono- and tri-methylamines and their derivatives, which are key intermediates for products such as Metformin. During Q1 FY27, Sayakha’s methylamine facility had reached around 65% utilisation.
While management has structurally allocated approximately 50% of this capacity for captive consumption, Aarti Drugs was still procuring 60% to 70% of its intermediate requirements externally during the quarter as the plant was in its initial ramp-up phase. Management expects internal captive fulfillment to accelerate to 80% to 90% across the September and December quarters.
That changes the way the capex needs to be analysed. If Sayakha supplies intermediates internally, the benefit may not show up as a proportionate increase in external sales. Instead, Aarti Drugs can potentially reduce its dependence on externally sourced inputs and retain more value within its own manufacturing chain.
Management explicitly said the captive component would add to gross margins more than revenue itself, making utilization at Sayakha an important monitorable for the investment cycle.
Metformin Is The Main Link
The captive-consumption opportunity is closely tied to Aarti Drugs’ expansion in Metformin, which is manufactured at the company’s Sarigam facility. The company currently operates around 1,400 tonnes per month (TPM) of Metformin capacity at Sarigam, which management plans to increase toward 2,200 TPM. This expansion includes scaling non-USFDA capacity to 1,700 TPM, alongside an additional 500–550 TPM dedicated block aimed at USFDA-regulated markets.
As Metformin production increases at Sarigam, a larger internal supply of key intermediates from Sayakha can reduce reliance on third-party procurement and give Aarti Drugs greater control over the supply chain.
The Capex Has More Than One Revenue Lever
Aarti Drugs’ ₹600 crore investment is not restricted to Sayakha. The company describes the completed programme as involving brownfield and greenfield capacity expansion, backward integration and de-bottlenecking, with the stated objective of supporting revenue growth, higher margins and improved RoCE. It estimates around ₹1,200 crore of revenue plus ₹300 crore of captive consumption, with an expected asset-turn framework of around 2.5x.
This makes the eventual payoff broader than simply adding external sales. Some assets can directly generate market revenue, while others can strengthen the economics of existing products by reducing the cost base. That distinction is important for investors because a rise in revenue alone may not fully capture the economic benefit of the investment.
Utilisation Is The Next Trigger
The biggest variable now is utilization. Sayakha operated at nearly 65% utilization in Q1 FY27, and management said there is scope for further improvement. The company expects higher utilization to improve operating efficiency, while the CFO highlighted that the newly completed Phase-1 greenfield assets have an estimated asset turnover of around 1.5x.
Phase-2 brownfield projects, however, will achieve materially higher asset turns of 3x to 4x because foundational infrastructure, such as effluent-treatment plants (ETPs) and common utilities, is already fully funded and operational. This suggests that the economics of future spending could improve as Aarti Drugs increasingly builds on an existing infrastructure base.
Q1 Margins Show Early Benefits
The early financial performance provides some evidence that operating leverage is beginning to appear. Consolidated Q1 FY27 revenue increased 19% YoY to ₹703.6 crore, while EBITDA grew 30% to ₹96.9 crore. The reported EBITDA margin expanded to 13.8%; however, Q1 absorbed a ₹2 crore one-off write-off for aging Capital Work-in-Progress (CWIP). Normalized for this write-off, the consolidated EBITDA margin had already crossed 14.0%.
It is important to note that the quarter’s strong realisations were heavily influenced by supply tightness and geopolitical disruptions; aggregate volume growth stood at just 3.5%, while price realisation growth drove 16% to 17% of the YoY expansion
That makes the captive-consumption story particularly relevant. If margins remain supported after temporary pricing benefits fade, it would provide stronger evidence that the improvement is coming from structural factors such as integration, utilisation and manufacturing efficiency.
Other Projects Are Adding To The Optionality
The ₹600 crore capex cycle comprises two flagship greenfield projects: Sayakha and the Tarapur salicylic acid facility. Tarapur is currently a drag on earnings, producing only 67 tonnes in Q1 due to aggressive Chinese price dumping and a delayed anti-dumping duty. To offset this and reach breakeven, management is commissioning a 350–400 TPM multipurpose plant to convert salicylic acid into higher-margin derivatives like methyl salicylate.
Furthermore, Aarti Drugs is progressing with a brownfield expansion at Baddi that will nearly double its oral-solid-dosage manufacturing capacity, and is planning a quasi-greenfield expansion adjacent to its USFDA-approved E-22 plant to double capacity across three new multipurpose lines.
The key feature of Aarti Drugs’ ₹600 crore capex programme is that not all of its benefits will necessarily appear as incremental revenue. Sayakha’s backward integration can support the growing Metformin business internally, potentially reducing input costs and improving gross margins as utilisation increases.
At the same time, the broader investment programme is designed to add capacity, expand regulated-market opportunities and improve asset turns. Q1 FY27’s margin expansion offers an early indication of operating leverage, although part of the quarter’s performance was also supported by favourable pricing conditions.
The next phase therefore comes down to utilisation and conversion of the new assets into sustainable economics. For investors, Sayakha utilisation, the share of captive consumption, Metformin volume growth, asset turns and EBITDA margins will be the clearest indicators of whether Aarti Drugs’ large investment cycle is translating into the structural improvement in profitability that management is targeting